Centessa Pharmaceuticals (NASDAQ:CNTA) Now Covered by Analysts at Oppenheimer

Oppenheimer began coverage on shares of Centessa Pharmaceuticals (NASDAQ:CNTA) in a research note released on Thursday morning, MarketBeat.com reports. The brokerage issued an outperform rating and a $14.00 target price on the stock.

Several other analysts have also issued reports on the company. Morgan Stanley upped their target price on Centessa Pharmaceuticals from $8.00 to $11.00 and gave the stock an equal weight rating in a report on Friday, June 21st. BMO Capital Markets reiterated an outperform rating and issued a $15.00 price target on shares of Centessa Pharmaceuticals in a research note on Monday, April 1st. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of Moderate Buy and a consensus price target of $11.00.

Centessa Pharmaceuticals Price Performance

NASDAQ CNTA opened at $9.43 on Thursday. Centessa Pharmaceuticals has a 12-month low of $5.15 and a 12-month high of $12.45. The firm’s 50 day moving average is $8.98 and its 200-day moving average is $9.48. The company has a market capitalization of $947.55 million, a PE ratio of -6.64 and a beta of 1.40. The company has a quick ratio of 10.37, a current ratio of 10.37 and a debt-to-equity ratio of 0.36.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings results on Monday, May 13th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.03. Equities research analysts anticipate that Centessa Pharmaceuticals will post -1.62 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Centessa Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CNTA. Lynx1 Capital Management LP bought a new position in shares of Centessa Pharmaceuticals in the first quarter valued at about $197,000. Farallon Capital Management LLC bought a new position in Centessa Pharmaceuticals in the 1st quarter valued at about $4,192,000. Artal Group S.A. lifted its position in Centessa Pharmaceuticals by 39.5% during the first quarter. Artal Group S.A. now owns 1,412,500 shares of the company’s stock worth $15,961,000 after acquiring an additional 400,000 shares during the last quarter. First Light Asset Management LLC bought a new stake in shares of Centessa Pharmaceuticals during the first quarter worth approximately $33,923,000. Finally, Price T Rowe Associates Inc. MD grew its position in shares of Centessa Pharmaceuticals by 16.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,958,079 shares of the company’s stock valued at $33,427,000 after purchasing an additional 418,615 shares during the last quarter. 82.01% of the stock is owned by institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.